Molecular biomarkers have transformed the biological definition of Alzheimer’s disease (AD), but they do not directly quantify the dynamic consequences of pathology on brain function. Sleep quantitative electroencephalography (qEEG) provides a complementary functional readout. We frame sleep qEEG as an artificial-intel...
Lorena Gallego-Viñarás, A. Gaeta, F. Barbé et al.· Emerging Topics in Artificia...· 0 citations
Understanding of the genetic architecture of AD in the context of its main genetic driver is improved, and APOE-stratified insights may help understand and overcome side effects, inform clinical trial enrollment strategies, and create the scientific basis for targeted, mechanism-driven therapies in neurodegenerative di...
J. Thomassen, H. Leonard, Brittany Ulms et al.· Nature Genetics· 0 citations
In biomarker-confirmed AD, NREM SP and SO activity are associated with CSF orexin concentrations and moderate associations between orexin and longitudinal cognitive and neuropsychiatric outcomes, independent of Aβ42 and tau.
Arsenio Páez, G. Piñol-Ripoll, A. Carnes-Vendrell et al.· Neurology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.